GSK.L : Summary for GLAXOSMITHKLINE PLC ORD 25P - Yahoo Finance

U.S. Markets closed

GlaxoSmithKline plc (GSK.L)


LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
1,670.50-4.50 (-0.27%)
At close: 5:12PM GMT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close1,675.00
Open1,677.50
Bid1,659.00 x 175400
Ask1,678.00 x 417900
Day's Range1,662.25 - 1,677.50
52 Week Range1,363.00 - 1,745.56
Volume6,973,395
Avg. Volume7,647,233
Market Cap81.08B
Beta1.20
PE Ratio (TTM)89.81
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.01 (4.90%)
Ex-Dividend DateN/A
1y Target EstN/A
  • Market Realist1 hour ago

    Exploring Novartis’s 2016 Revenue

    Novartis (NVS) reported no change in its revenue on a constant currency basis in 2016 compared to 2015. The company's 2016 revenue fell to $48.5 billion.

  • Investopedia8 hours ago

    Big Decision Week for Roche, GSK, Sanofi, Mylan

    Big pharma companies eagerly await key decisions on drugs from the FDA next week.

  • Reutersyesterday

    Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency

    Three of Europe's top drugmakers face critical verdicts from U.S. regulators next week, with Sanofi and Roche likely to win approvals for two new products, while GlaxoSmithKline braces for a potential generic rival. Given earlier impressive clinical trial results, investors expect the Food and Drug Administration (FDA) to clear both Roche's multiple sclerosis (MS) treatment Ocrevus and Sanofi's new eczema drug Dupixent.